XNK Therapeutics AB (“XNK”) today announced that Vinnova, a Swedish government-sponsored innovation agency, has granted XNK SEK1 million to upscale production of CellProtect.
“We are extremely pleased to gain the support of Vinnova as we develop our therapy platform CellProtect for future clinical trials,” said Karin Mellström, CEO of XNK Therapeutics. “The grant funding will go a long way in taking our innovative technology to the next level.”
For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit xnktherapeutics.com.
About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.
